Sang Hyun Kim, Sanghoon Shin, Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Chan Joon Kim, Mahn-Won Park, Min Chul Kim, Byung-Hee Hwang, Kwan Yong Lee, Yun-Seok Choi, Hee-Yeol Kim, Ki-Dong Yoo, Doo Soo Jeon, Youngkeun Ahn, Kiyuk Chang
BACKGROUND: Dyspnoea is frequent during ticagrelor-based dual antiplatelet therapy (DAPT) for acute myocardial infarction (AMI). However, its clinical characteristics or management strategy remains uncertain. METHODS: The study assessed 2,617 AMI patients from the Ticagrelor versus Clopidogrel in Stabilized Patients with AMI (TALOS-AMI) trial. Dyspnoea during 1-month ticagrelor-based DAPT and following DAPT strategies with continued ticagrelor or de-escalation to clopidogrel from 1 to 12 months were evaluated for drug adherence, subsequent dyspnoea, major adverse cardiovascular events (MACE), and bleeding events...
April 4, 2024: Thrombosis and Haemostasis